Begoña Bermejo
- Cancer Research top 2%
- Breast Cancer Treatment Studies 30
- Cancer Genomics and Diagnostics 11
- MicroRNA in disease regulation 11
- Oncology top 2%
- HER2/EGFR in Cancer Research 35
- Cancer Treatment and Pharmacology 30
- Cancer Immunotherapy and Biomarkers 12
-
- Advanced Breast Cancer Therapies 39
- Reproductive Medicine top 5%
-
- PI3K/AKT/mTOR signaling in cancer 7
Begoña Bermejo
135 papers receiving 2.5k citations
Hit Papers
Peers
Comparison fields: 5 of 119
- Cancer Research 924
- Oncology 1.5k
- Pulmonary and Respiratory Medicine 544
- Reproductive Medicine 126
- Critical Care and Intensive Care Medicine 67
Countries citing papers authored by Begoña Bermejo
This map shows the geographic impact of Begoña Bermejo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Begoña Bermejo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Begoña Bermejo more than expected).
Fields of papers citing papers by Begoña Bermejo
This network shows the impact of papers produced by Begoña Bermejo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Begoña Bermejo. The network helps show where Begoña Bermejo may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Begoña Bermejo, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 2 | |
| 2 | 2024 | 5 | |
| 3 | 2023 | 10 | |
| 4 | 2023 | 4 | |
| 5 | 2023 | 23 | |
| 6 | 2023 | 23 | |
| 7 | Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized studybreakdown → | 2022 | 204 |
| 8 | 2021 | 31 | |
| 9 | 2021 | 78 | |
| 10 | 2021 | 13 | |
| 11 | 2021 | 20 | |
| 12 | 2021 | 15 | |
| 13 | 2021 | 8 | |
| 14 | 2021 | 30 | |
| 15 | 2020 | 14 | |
| 16 | 2020 | 27 | |
| 17 | 2020 | 9 | |
| 18 | 2019 | 71 | |
| 19 | 2010 | 2 | |
| 20 | Vigilancia y control de las infecciones nosocomiales: EPINE, VICONOS, PREVINE, ENVIN-UCI | 2009 | 5 |
About Begoña Bermejo
Begoña Bermejo is a scholar working on Cancer Research, Oncology and Pulmonary and Respiratory Medicine, having authored 143 papers that have together received 2.5k indexed citations. Recurring topics across this work include Advanced Breast Cancer Therapies (39 papers), HER2/EGFR in Cancer Research (35 papers), Breast Cancer Treatment Studies (30 papers), Cancer Treatment and Pharmacology (30 papers), Cancer Immunotherapy and Biomarkers (12 papers), Cancer Genomics and Diagnostics (11 papers), MicroRNA in disease regulation (11 papers) and PI3K/AKT/mTOR signaling in cancer (7 papers). The work is most often cited by research in Cancer Research (924 citations), Oncology (1.5k citations) and Pulmonary and Respiratory Medicine (544 citations). Begoña Bermejo has collaborated with scholars based in Spain, United States and Italy. Frequent co-authors include Aňa Lluch, Juan Miguel Cejalvo, María Vidal, Pîlar Eroles, Giampaolo Bianchini, María Teresa Martínez, Aleix Prat, Semiglazov Vf, Luca Gianni and Cristina Hernándo. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Cancer Research, Clinical & Translational Oncology and International Journal of Molecular Sciences.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.